Vanda ’s latest study failed. But revenue grew in 2019.
The D.C. biotech ’s phase 3 clinical trial of a drug candidate failed to reduce symptoms among adult patients with an itchy skin condition called atopic dermatitis.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Sara Gilgore Source Type: news
More News: Biotechnology | Clinical Trials | Dermatitis | Dermatology | Health Management | Itchiness | Skin | Study